Latest & greatest articles for estradiol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on estradiol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on estradiol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for estradiol

21. Update on the effect of estradiol in postmenopause women with Alzheimer's disease: a systematic review. (Abstract)

Update on the effect of estradiol in postmenopause women with Alzheimer's disease: a systematic review. Estradiol (E2) has been used in the treatment of Alzheimer's disease (AD) for many years but with various responses. Evidence from clinical studies, randomized clinical trials (RCTs), and observational studies further underscores the importance of E2 in postmenopause women diagnosed with AD. The purpose of this article is to review all clinical trials to date focusing on the E2 in AD patients

2016 Acta neurologica Belgica

22. Testosterone, Estradiol, and Sex Hormone-Binding Globulin in Alzheimer's Disease: A Meta-Analysis. (Abstract)

Testosterone, Estradiol, and Sex Hormone-Binding Globulin in Alzheimer's Disease: A Meta-Analysis. Previous studies suggested that plasma sex hormones may be implicated in the pathogenesis of Alzheimer's disease (AD). However, the relationship between sex hormones and AD remains unclear.To systematically review and quantitatively analyze studies observing plasma total testosterone (TT), estradiol (E2), and sex hormone-binding globulin (SHBG) levels among AD patients.Medline, EMBASE

2015 Current Alzheimer research

23. Comparative efficacy and safety of estradiol transdermal preparations for the treatment of vasomotor symptoms in postmenopausal women: an indirect comparison meta-analysis. (Abstract)

Comparative efficacy and safety of estradiol transdermal preparations for the treatment of vasomotor symptoms in postmenopausal women: an indirect comparison meta-analysis. Divigel and Estrogel are estradiol gels for the treatment of postmenopausal women with moderate to severe vasomotor symptoms. They differ with respect to several factors including estradiol concentration and surface application, and cannot be compared solely on the basis of their estradiol dose. No randomized clinical trials (...) have compared them head to head, but both have been compared with placebo. Therefore, the objective of this study was to conduct a systematic review and network meta-analysis of the two estradiol gels.We performed a comprehensive systematic literature review. One publication reporting on one Divigel trial, three publications reporting on two Estrogel trials, and five publications reporting on other estradiol transdermal preparations were identified. Efficacy outcomes were change from baseline

2015 Menopause (New York, N.Y.)

24. EFFICACY OF ESTRADIOL IN PERIMENOPAUSAL DEPRESSION: SO MUCH PROMISE AND SO FEW ANSWERS. (Full text)

EFFICACY OF ESTRADIOL IN PERIMENOPAUSAL DEPRESSION: SO MUCH PROMISE AND SO FEW ANSWERS. Controversy regarding the antidepressant efficacy of hormone replacement therapy (HRT) stems almost from its inception and reflects the same methodological inconsistencies that have compromised efforts to determine whether the perimenopause is accompanied by an increase in mood symptoms or depression. Methodologic differences of note (other than study design) include menopausal state (perimenopause vs (...) were solely perimenopausal.One can generalize from the studies reviewed here only with great caution, but there is little evidence to support the use of estradiol to improve mood in nondepressed patients (not surprisingly) and some evidence to support the antidepressant efficacy of estradiol in perimenopausal but not postmenopausal women.© 2015 Wiley Periodicals, Inc.

2015 Depression and anxiety PubMed abstract

25. The effects of estradiol on mood and behavior in human female adolescents: a systematic review. (Full text)

The effects of estradiol on mood and behavior in human female adolescents: a systematic review. Mood disorders and health risk behaviors increase in adolescence. Puberty is considered to contribute to these events. However, the precise impact of pubertal hormone changes to the emergence of mood disorders and risk behaviors is relatively unclear. It is important that inappropriate attribution is not made. Our aim was to determine what is known about the effect of endogenous estradiol on human (...) adolescent girls' mood and behavior. The databases searched were MEDLINE, Embase, PsycINFO, Education Resources Information Center (ERIC), Pre-MEDLINE, Web of Science, and Scopus for all dates to October 2014. For inclusion, contemporaneous hormone and mood or behavioral assessment was required. Data were extracted following a template created by the authors. Fourteen studies met our inclusion criteria. There was some consistency in findings for mood and estradiol levels, with associations between

2015 European journal of pediatrics PubMed abstract

26. Low-dose transdermal estradiol for vasomotor symptoms: a systematic review. (Full text)

Low-dose transdermal estradiol for vasomotor symptoms: a systematic review. This review aims to determine the effectiveness of low-dose transdermal estrogen versus placebo in postmenopausal women with moderate to severe hot flashes.We conducted a systematic review of studies by searching Medline and EMBASE using the following inclusion criteria: double-blind, placebo-controlled, randomized controlled trials conducted in postmenopausal women with at least 7 hot flashes per day and/or at least 50

2015 Menopause PubMed abstract

27. Effects of luteal estradiol pre-treatment on the outcome of IVF in poor ovarian responders. (Abstract)

Effects of luteal estradiol pre-treatment on the outcome of IVF in poor ovarian responders. In view of the discrepancies about the luteal estradiol treatment before stimulation protocols having some potential advantages compared with the standard protocols in poor ovarian responders undergoing IVF, a meta-analysis of the published data was performed to compare the efficacy of the luteal estradiol pre-treatment protocols in IVF poor response patients.We searched for all published articles (...) . The searches yielded 32 articles, from which seven studies met the inclusion criteria. We performed this meta-analysis involving 450 IVF patients in luteal estradiol pre-treatment protocol group and 606 patients in standard protocol group.The luteal estradiol protocol resulted in a significantly higher duration of stimulation compared with the standard protocol. In addition, the number of oocytes retrieved and mature oocytes retrieved were significantly higher in the luteal estradiol protocols than those

2013 Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

28. Lo Minastrin Fe (norethindrone acetate and ethinyl estradiol chewable tablets and ethinyl estradiol tablets and ferrous fumarate tablets)

Lo Minastrin Fe (norethindrone acetate and ethinyl estradiol chewable tablets and ethinyl estradiol tablets and ferrous fumarate tablets) Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Lo Minastrin Fe (norethindrone acetate and ethinyl estradiol chewable tablets and ethinyl estradiol tablets and ferrous fumarate tablets) Company: Warner Chilcott Company, LLC Application No.: 204654 Approval Date: 7

2013 FDA - Drug Approval Package

29. Norethindrone Acetate and Ethinyl Estradiol Chewable Tablets and Ferrous Fumarate Tablets

Norethindrone Acetate and Ethinyl Estradiol Chewable Tablets and Ferrous Fumarate Tablets Drug Approval Package: Norethindrone Acetate and Ethinyl Estradiol NDA #203667 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Norethindrone Acetate and Ethinyl Estradiol Chewable Tablets and Ferrous Fumarate Tablets Company: Warner Chilcott Company, LLC Application No.: 203667 Approval Date: 05/08/2013 Persons with disabilities having problems accessing the PDF

2013 FDA - Drug Approval Package

30. NuvaRing (etonogestrel/ethinyl estradiol) Vaginal Ring

NuvaRing (etonogestrel/ethinyl estradiol) Vaginal Ring Drug Approval Package: NuvaRing (etonogestrel/ethinyl estradiol) Vaginal Ring U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: NuvaRing (etonogestrel/ethinyl estradiol) Vaginal Ring NuvaRing (etonogestrel/ethinyl estradiol) Vaginal Ring NuvaRing (etonogestrel/ethinyl estradiol) Vaginal Ring Company: Organon USA Inc. Application No.: 021187s021s022 Approval Date: 10/04/2013 Persons

2013 FDA - Drug Approval Package

31. Combined oral contraception: nomegestrol/estradiol (Zoely)

Combined oral contraception: nomegestrol/estradiol (Zoely) Combined or Combined oral contr al contraception: nomegestrol/ aception: nomegestrol/ estr estradiol (Z adiol (Zoely) oely) Evidence summary Published: 17 December 2013 nice.org.uk/guidance/esnm28 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in December 2013. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE (...) websites for up-to-date information. Summary Nomegestrol/estradiol (Zoely) has similar contraceptive efficacy to drospirenone/ethinylestradiol (Yasmin) with similar numbers of days of unscheduled bleeding, fewer days of withdrawal bleeding and significantly more absence of withdrawal bleeding. Acne and weight gain were reported more frequently in women taking nomegestrol/estradiol than in women taking drospirenone/ ethinylestradiol (statistical significance not reported). © NICE 2018. All rights

2013 National Institute for Health and Clinical Excellence - Advice

32. Cycle cancellation and pregnancy after luteal estradiol priming in women defined as poor responders: a systematic review and meta-analysis. (Full text)

Cycle cancellation and pregnancy after luteal estradiol priming in women defined as poor responders: a systematic review and meta-analysis. Does a luteal estradiol (LE) stimulation protocol improve outcomes in poor responders to IVF?LE priming is associated with decreased cycle cancellation and increased chance of clinical pregnancy in poor respondersPoor responders to IVF are one of the most challenging patient populations to treat. Many standard protocols currently exist for stimulating

2013 Human reproduction (Oxford, England) PubMed abstract

33. Hormonal contraceptives with ethinyl estradiol were associated with increased thrombotic stroke and MI. (Abstract)

Hormonal contraceptives with ethinyl estradiol were associated with increased thrombotic stroke and MI. 23070511 2013 01 14 2012 10 16 1539-3704 157 8 2012 Oct 16 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. Hormonal contraceptives with ethinyl estradiol were associated with increased thrombotic stroke and MI. JC4-9 10.7326/0003-4819-157-8-201210160-02009 Andrews Jeff J eng Comment Journal Article United States Ann Intern Med 0372351 0003-4819 N Engl J Med. 2012 Jun 14;366(24

2012 Annals of Internal Medicine

34. Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial (Full text)

Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial The purpose of this study was to evaluate whether oral naproxen or transdermal estradiol decreases bleeding and spotting in women who are initiating the levonorgestrel-releasing intrauterine system.We conducted a randomized controlled trial of naproxen, estradiol, or placebo that was administered over the first 12 weeks of levonorgestrel-releasing intrauterine system use (...) . Participants completed a written bleeding diary. We imputed missing values and performed an intention-to-treat analysis.There were 129 women who were assigned randomly to naproxen (n = 42 women), estradiol (n = 44 women), or placebo (n = 43 women). The naproxen group was more likely to be in the lowest quartile of bleeding and spotting days compared with placebo (42.9% vs 16.3%; P = .03). In the multivariable analysis, the naproxen group had a 10% reduction in bleeding and spotting days (adjusted relative

2012 EvidenceUpdates Controlled trial quality: predicted high PubMed abstract

35. Subcutaneous implantation of estradiol pellets for postmenopausal disorders

Subcutaneous implantation of estradiol pellets for postmenopausal disorders Subcutaneous implantation of estradiol pellets for postmenopausal disorders Subcutaneous implantation of estradiol pellets for postmenopausal disorders Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Subcutaneous implantation of estradiol pellets for postmenopausal disorders. Lansdale (...) replacement therapy (HRT), which typically involves administration of estrogen and progesterone via pills, skin patches, or gels. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Estradiols; Postmenopause Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax

2012 Health Technology Assessment (HTA) Database.

36. Zoely - nomegestrol / estradiol

Zoely - nomegestrol / estradiol 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union Assessment report Zoely International Non proprietary Name: nomegestrol/estradiol Procedure No. EMEA/H/C/001213 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted Table of contents 1. Background (...) exception contain 17- alpha-ethinylestradiol (EE) and some first generation combined hormonal contraceptives contain mestranol. 19-nor-testosteron derivatives have, besides their gestagenic effects, mild to moderate androgenic effects and might have negative impact on the lipid metabolism. They can also cause intrahepatic cholestasis. Nomegestrol Acetate (NOMAC) is a highly selective progestin derived from the naturally occurring steroid hormone, progesterone. The 17 ß-estradiol (E2) compound

2011 European Medicines Agency - EPARs

37. Ioa - nomegestrol acetate / estradiol

Ioa - nomegestrol acetate / estradiol 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8613 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union Assessment report Ioa nomegestrol/estradiol Procedure No.: EMEA/H/C/002068 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Medicinal product no longer authorisedIoa CHMP assessment (...) Pharmaceutical Ingredient AST Aspartate Aminotransferase AUC Area Under the Curve BE Bioequivalence BMI Body Mass Index CI Confidence Interval Cmax Maximum Plasma Concentration Cmax,ss,cor Maximum Plasma Concentration at steady state, corrected for the residual concentration of previous doses CBG Corticosteroid Binding Globulin COC Combined Oral Contraceptive CRP C-reactive protein CTR Clinical trial report DRSP-EE Drospirenone - Ethinyl Estradiol E1 Estrone E1S Estrone sulphate E2 17 ß-estradiol FD Follicle

2011 European Medicines Agency - EPARs

38. Subcutaneous implantation of estradiol pellets for postmenopausal disorders

Subcutaneous implantation of estradiol pellets for postmenopausal disorders Subcutaneous implantation of estradiol pellets for postmenopausal disorders Subcutaneous implantation of estradiol pellets for postmenopausal disorders Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Subcutaneous implantation of estradiol pellets for postmenopausal disorders. Lansdale (...) by use of hormone replacement therapy (HRT), which typically involves administration of estrogen and progesterone via pills, skin patches, or gels. Timeliness warning This report has been archived and may contain outdated information. To request a copy of the report please contact the organisation directly. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Drug Implants; Estradiol; Estrogen Replacement Therapy; Females; Menopause Language Published English Country

2011 Health Technology Assessment (HTA) Database.

39. Norethindrone and Ethinyl estradiol chewable tablets and ferrous fumarate chewable tablets

Norethindrone and Ethinyl estradiol chewable tablets and ferrous fumarate chewable tablets Drug Approval Package: Norethindrone and Ethinyl estradiol NDA #022573 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Norethindrone and Ethinyl estradiol chewable tablets and ferrous fumarate chewable tablets Company: Warner Chilcott, LLC Application No.: 022573 Approval Date: 12/22/2010 Persons with disabilities having problems accessing the PDF files below may

2010 FDA - Drug Approval Package

40. Safyral (drospirenone/ethinyl estradiol/levomefolate calcium tablets and levomefolate calcium tablets)

Safyral (drospirenone/ethinyl estradiol/levomefolate calcium tablets and levomefolate calcium tablets) Drug Approval Package: Safyral (drospirenone/ethinyl estradiol) NDA #022574 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Safyral (drospirenone/ethinyl estradiol/levomefolate calcium tablets and levomefolate calcium tablets) Company: Bayer HealthCare Pharmaceuticals Inc. Application No.: 022574 Approval Date: 12/16/2010 Persons with disabilities

2010 FDA - Drug Approval Package